Selleck Chemicals supplies over 120,000 inhibitors used in the study of cell signaling pathways. We actively tracks the latest science so our customers can rely on us to be the leading supplier of the newest inhibitors. Selleck's Bioactive Screening Libraries consist of over 8,000 small molecules with validated biological and pharmacological activities. The safety and effectiveness of these molecules has been demonstrated through preclinical and clinical research and many of them are FDA-approved compounds.
Product | Code | Price | ||
---|---|---|---|---|
Cetuximab (anti-EGFR) | A2000 5mg | 5mg |
€ 728,70 | Contact us |
Cetuximab (anti-EGFR) | A2000 1mg | 1mg |
€ 243,60 | Contact us |
Ipilimumab (anti-CTLA-4) | A2001 5mg | 5mg |
€ 2.060,10 | Contact us |
Ipilimumab (anti-CTLA-4) | A2001 20mg | 20mg |
€ 5.767,65 | Contact us |
Ipilimumab (anti-CTLA-4) | A2001 1mg | 1mg |
€ 687,75 | Contact us |
Nivolumab (anti-PD-1) | A2002 5mg | 5mg |
€ 728,70 | Contact us |
Ramucirumab (anti-VEGFR2) | A2003 5mg | 5mg |
€ 728,70 | Contact us |
Atezolizumab (anti-PD-L1) | A2004 5mg | 5mg |
€ 728,70 | Contact us |
Atezolizumab (anti-PD-L1) | A2004 25mg | 25mg |
€ 2.186,10 | Contact us |
Pembrolizumab (anti-PD-1) | A2005 5mg | 5mg |
€ 728,70 | Contact us |
Bevacizumab (anti-VEGF) | A2006 5mg | 5mg |
€ 728,70 | Contact us |
Bevacizumab (anti-VEGF) | A2006 1mg | 1mg |
€ 243,60 | Contact us |